BIOCRYST PHARMACEUTICALS, INC. (BCRX) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30..
Borrowing debt
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | (m) | |
| Borrowing debt due after one year | 395.40M USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current |
| Borrowing debt | (m) | Long-term Debt, Excluding Current Maturities |
| Total assets | 557.85M USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | (m) | $395.40M | (m) | (m) | $557.85M | (m) |
| 2026-03-31 | (m) | (m) | (m) | $395.20M | (m) | (m) | $465.05M | (m) |
| 2025-12-31 | (m) | (m) | (m) | $0.00 | (m) | (m) | $514.16M | (m) |
| 2025-09-30 | (m) | (m) | (m) | $194.37M | (m) | (m) | $446.42M | (m) |
| 2025-06-30 | (m) | (m) | (m) | $242.79M | (m) | (m) | $457.19M | (m) |
| 2025-03-31 | (m) | (m) | (m) | $315.41M | (m) | (m) | $480.05M | (m) |
| 2024-12-31 | (m) | (m) | (m) | $314.87M | (m) | $320.85M | $490.42M | (m) |
| 2024-09-30 | (m) | (m) | (m) | $314.33M | (m) | $330.01M | $491.25M | (m) |
| 2024-06-30 | (m) | (m) | (m) | $313.82M | (m) | $272.03M | $472.42M | (m) |
| 2024-03-31 | (m) | (m) | (m) | $308.48M | (m) | $336.55M | $467.89M | (m) |
| 2023-12-31 | (m) | (m) | (m) | $303.23M | (m) | $388.99M | $516.96M | (m) |
| 2023-09-30 | (m) | (m) | (m) | $298.00M | (m) | $397.59M | $522.92M | (m) |
| 2023-06-30 | (m) | (m) | (m) | $293.18M | (m) | $410.67M | $529.88M | (m) |
| 2023-03-31 | (m) | (m) | (m) | $232.52M | (m) | $398.16M | $509.74M | (m) |
| 2022-12-31 | (m) | (m) | (m) | $231.62M | (m) | $424.31M | $550.00M | (m) |
| 2022-09-30 | (m) | (m) | (m) | $223.87M | (m) | $426.86M | $558.59M | (m) |
| 2022-06-30 | (m) | (m) | (m) | $144.52M | (m) | $417.48M | $510.54M | (m) |
| 2022-03-31 | (m) | (m) | (m) | $140.24M | (m) | $443.47M | $527.72M | (m) |
| 2021-12-31 | (m) | (m) | (m) | $136.08M | (m) | $507.60M | $588.15M | (m) |
| 2021-09-30 | (m) | (m) | (m) | $132.05M | (m) | $199.60M | $265.76M | (m) |
| 2021-06-30 | (m) | (m) | (m) | $126.80M | (m) | $218.43M | $277.28M | (m) |
| 2021-03-31 | (m) | (m) | (m) | $123.04M | (m) | $240.36M | $284.43M | (m) |
| 2020-12-31 | (m) | (m) | (m) | $119.73M | (m) | $300.37M | $334.71M | (m) |
| 2019-12-31 | (m) | (m) | (m) | $0.00 | (m) | $136.23M | $175.28M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |